Unspecified adverse effect of drug or medicament. Unspecified adverse effect of drug or medicament
Conditions
Interventions
Intervention 1: Intervention group: Patients in group A will receive 1 mg/kg of aminophylline diluted in 30 ml of 0.9% saline intravenously 10 minutes before admission to the endoscopy room. Intraveno
Sponsors
Vice President for Research and Technology, Guilan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: All patients 20 years of age and older who referred to the Rasht Gastroenterology Clinic in 2025 for upper gastrointestinal endoscopy American Society of Anesthesiologists (ASA Class I,II)
Exclusion criteria
Exclusion criteria: Any history of sensitivity to aminophylline or drug components people with any liver dysfunction including liver cirrhosis, fatty liver, etc. due to differences in drug metabolism and drug efficacy consequences from healthy people smokers due to the effect of smoking on aminophylline drug metabolism and changes in drug pharmacokinetics people who have recently received or are currently taking cimetidine, ciprofloxacin, and macrolides such as erythromycin and clarithromycin due to changes in aminophylline metabolism and drug efficacy consequences people with a history of any type of arrhythmia or neurological disorder such as epilepsy, and patient dissatisfaction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eye opening time. Timepoint: From administering the last medicine to opening the patient's eyes with a sound. Method of measurement: Timer.;Recovery time in minutes. Timepoint: Time between endoscope removal and patient regaining full consciousness. Method of measurement: Timer.;Endoscopy time. Timepoint: Time from endoscope insertion to complete endoscope removal. Method of measurement: Timer.;Mean blood pressure. Timepoint: At baseline time T0 (before aminophylline injection), T1 (before anesthesia induction), T2 (after propofol administration), T3 (after 3 minutes), T4 (time of patient transfer to the recovery ward). Method of measurement: Barometer.;Arterial blood oxygen saturation percentage. Timepoint: Baseline time T0 (before aminophylline injection), T1 (before anesthesia induction), T2 (after propofol administration), T3 (after 3 minutes), T4 (time of patient transfer to the recovery room). Method of measurement: Pulse oximeter.;Heart rate. Timepoint: Baseline time T0 (before aminophylline injection), T1 (before induction of anesthesia), T2 (after administration of propofol), T3 (after 3 minutes), T4 (time of transfer of patients to the recovery ward. Method of measurement: Vital signs monitoring device. | — |
Secondary
| Measure | Time frame |
|---|---|
| Major complications (need for intensive care, severe hemodynamic disturbances, and resuscitation). Timepoint: During endoscopy. Method of measurement: Bedside observation of the patient during endoscopy and vital signs monitoring device.;Minor side effects (dizziness, chest discomfort, and transient arrhythmia without hemodynamic fluctuations, restlessness, oxygen saturation less than 90% for more than 10 seconds, blood pressure drop more than 20%, heart rate drop more than 20%, tachycardia more than 100 beats per minute, headache, nausea, and vomiting). Timepoint: During endoscopy. Method of measurement: ?????? ?? ????? ????? ??? ????????? ? ?????? ?????????? ????? ?????. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Hossein Khoshrang
Anesthesia Research Center
Outcome results
None listed